View source for Cardiomyopathy cost-effectiveness of therapy
Jump to navigation
Jump to search
You do not have permission to edit this page, for the following reason:
You can view and copy the source of this page.
Templates used on this page:
- Template:AE (view source)
- Template:CMG (view source)
- Template:Cardiomyopathy (view source)
- Template:Column-width (view source)
- Template:EdzelCo (view source)
- Template:Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Rowin EJ1, Maron BJ2, Abt P2, Kiernan MS3, Vest A3, Costantino F4, Maron MS2, DeNofrio D3: Am J Cardiol. 2018 Apr 15;121(8):986-996 (view source)
- Template:Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Citation data: American heart journal, ISSN: 1097-6744, Vol: 154, Issu (view source)
- Template:Main other (view source)
- Template:Reflist (view source)
- Template:WH (view source)
- Template:WS (view source)
- Template:WikiDoc CMG (view source)
- Module:Check for unknown parameters (view source)
Return to Cardiomyopathy cost-effectiveness of therapy.